- Home
- AMAL vs RGNX Comparison
AMAL vs RGNX Comparison
Compare AMAL & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AMAL | RGNX |
|---|---|---|
| Founded | 1923 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 800.8M | 661.2M |
| IPO Year | 2018 | 2015 |
Fundamental Metrics
Financial Performance| Metric | AMAL | RGNX |
|---|---|---|
| Price | $30.86 | $12.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $33.50 | $30.29 |
| AVG Volume (30 Days) | 175.9K | ★ 599.2K |
| Earning Date | 01-22-2026 | 11-06-2025 |
| Dividend Yield | ★ 1.86% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.32 | N/A |
| Revenue | ★ $306,936,000.00 | $161,318,000.00 |
| Revenue This Year | $10.09 | $198.02 |
| Revenue Next Year | $8.37 | $2.67 |
| P/E Ratio | $9.07 | ★ N/A |
| Revenue Growth | 1.29 | ★ 91.30 |
| 52 Week Low | $25.03 | $5.04 |
| 52 Week High | $37.26 | $13.93 |
Technical Indicators
Market Signals| Indicator | AMAL | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 66.62 | 58.14 |
| Support Level | $29.01 | $12.05 |
| Resistance Level | $31.02 | $13.80 |
| Average True Range (ATR) | 0.87 | 0.77 |
| MACD | 0.26 | 0.10 |
| Stochastic Oscillator | 94.56 | 70.97 |
Price Performance
Historical ComparisonAbout AMAL Amalgamated Financial Corp. (DE)
Amalgamated Financial Corp is a bank holding company. It is a full-service commercial bank and a chartered trust company. It provides commercial banking and trust services nationally and offers various products and services to commercial and retail customers. It offers a complete suite of commercial and retail banking, investment management and trust and custody services.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.